The enhanced antitumor effects of biodegradable cationic heparin-polyethyleneimine nanogels delivering HSulf-1 gene combined with cisplatin on ovarian cancer

International Journal of Oncology

Volumn 41, Issue 4, 2012, Pages 1504-1512

  Liu, Ping ^a,b   Gou, Maling ^a,b   Yi, Tao ^a,b   Qi, Xiaorong ^a,b   Xie, Chuan ^a,b   Zhou, Shengtao ^a,b   Deng, Hongxin ^a,b   Wei, Yuquan ^a,b   Zhao, Xia ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Apoptosis; Combination therapy; Heparin polyethyleneimine; HSulf 1; Ovarian cancer

Indexed keywords

CD31 ANTIGEN; CISPLATIN; HEPARAN SULFATE; HEPARAN SULFATE 6 ENDOSULFATASE 1; HEPARIN POLYETHYLENEIMINE NANOGEL; KI 67 ANTIGEN; POLYETHYLENEIMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; NICK END LABELING; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CISPLATIN; DRUG DELIVERY SYSTEMS; FEMALE; GENETIC THERAPY; HEPARIN; HUMANS; MICE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; SULFOTRANSFERASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866515124     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1558     Document Type: Article

References (40)

1. Shridhar V, Sen A, Chien J, Staub J, Avula R, Kovats S, Lee J, Lillie J and Smith DI: Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Cancer Res 62: 262-270, 2002.
2. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S and Rosen SD: Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem 277: 49175-49185, 2002.
3. Ai X, Do AT, Kusche-Gullberg M, Lindahl U, Lu K and Emerson CP Jr: Substrate specificity and domain functions of extracellular heparan sulfate 6-O-endosulfatases, QSulf1 and QSulf2. J Biol Chem 281: 4969-4976, 2006.
4. Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM and Emerson CP Jr: Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science 293: 1663-1666, 2001.
5. Selva EM and Perrimon N: Role of heparan sulfate proteoglycans in cell signaling and cancer. Adv Cancer Res 83: 67-80, 2001.
6. Lin X: Functions of heparan sulfate proteoglycans in cell signaling during development. Development 131: 6009-6021, 2004.
7. Lai JP, Chien J, Staub J, Avula R, Greene EL, Matthews TA, Smith DI, Kaufmann SH, Roberts LR and Shridhar V: Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 278: 23107-23117, 2003.
8. Lai JP, Chien J, Strome SE, Staub J, Montoya DP, Greene EL, Smith DI, Roberts LR and Shridhar V: HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 23: 1439-1447, 2004.
9. Lai JP, Chien JR, Moser DR, Staub JK, Aderca I, Montoya DP, Matthews TA, Nagorney DM, Cunningham JM, Smith DI, Greene EL, Shridhar V and Roberts LR: hSulf1 sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 126: 231-248, 2004.
10. Dai Y, Yang Y, MacLeod V, Yue X, Rapraeger AC, Shriver Z, Venkataraman G, Sasisekharan R and Sanderson RD: HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem 280: 40066-40073, 2005.
11. Narita K, Staub J, Chien J, Meyer K, Bauer M, Friedl A, Ramakrishnan S and Shridhar V: HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res 66: 6025-6032, 2006.
12. Liu P, Khurana A, Rattan R, Kalloger S, Dowdy S, Gilks B and Shridhar V: Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer. Cancer Res 69: 4843-4850, 2009.
13. Staub J, Chien J, Pan Y, Qian X, Narita K, Aletti G, Roberts LR, Molina J and Shridhar V: Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance. Oncogene 26: 4969-4978, 2007.
14. Lai JP, Sandhu DS, Shire AM and Roberts LR: The tumor suppressor function of human sulfatase 1 (SULF1) in carcinogenesis. J Gastrointest Cancer 39: 149-158, 2008.
15. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
16. Ozols RF: Progress in ovarian cancer: an overview and perspective. EJC (Suppl) 1: 43-55, 2003.
17. Gonzalez VM, Fuertes MA, Alonso C and Perez JM: Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59: 657-663, 2001.
18. Fuertes MA, Alonso C and Perez JM: Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 103: 645-662, 2003.
19. Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24: 331-344, 1998.
20. Cohen SM and Lippard SJ: Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 67: 93-130, 2001.
21. Edelstein ML, Abedi MR, Wixon J, Edelstein RM: Gene therapy clinical trials worldwide 1989-2004-an overview. J Gene Med 6: 597-602, 2004.
22. Anderson DG, Peng W, Akinc A, Hossain N, Kohn A, Padera R, Langer R and Sawicki JA: A polymer library approach to suicide gene therapy for cancer. Proc Natl Acad Sci USA 101: 16028-16033, 2004.
23. Ferber D: Gene therapy. Safer and virus-free? Science 294: 1638-1642, 2001.
24. Lv H, Zhang S, Wang B, Cui S and Yan J: Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 114: 100-109, 2006.
25. Neu M, Fischer D and Kissel T: Recent advances in rational gene transfer vector design based on poly(ethyleneimine) and its derivatives. J Gene Med 7: 992-1009, 2005.
26. Kunath K, von Harpe A, Fischer D, Petersen H, Bickel U, Voigt K and Kissel T: Low-molecular-weight polyethyleneimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethyleneimine. J Control Release 89: 113-125, 2003.
27. Wen Y, Pan S, Luo X, Zhang X, Zhang W and Feng M: A biodegradable low molecular weight polyethyleneimine derivative as low toxicity and efficient gene vector. Bioconjug Chem 20: 322-332, 2009.
28. Gosselin MA, Guo W and Lee RJ: Efficient gene transfer using reversibly cross-linked low molecular weight polyethyleneimine. Bioconjug Chem 12: 989-994, 2001.
29. Forrest ML, Koerber JT and Pack DW: A degradable polyethyleneimine derivative with low toxicity for highly efficient gene delivery. Bioconjug Chem 14: 934-940, 2003.
30. Jeon O, Yang HS, Lee TJ and Kim BS: Heparin-conjugated polyethyleneimine for gene delivery. J Control Release 132: 236-242, 2008.
31. Gou ML, Men K, Zhang J, Li YH, Song J, Luo S, Shi HS, Wen YJ, Guo G, Huang MJ, Zhao X, Qian ZY and Wei YQ: Efficient inhibition of C-26 colon carcinoma by VSVMP gene delivered by biodegradable cationic nanogel derived from polyethyleneimine. ACS Nano 4: 5573-5584, 2010.
32. Liu P, Gou ML, Yi T, Xie C, Qi XR, Zhou ST, Deng HX, Wei YQ and Zhao X: Efficient inhibition of an intraperitoneal xenograft model of human ovarian cancer by HSulf-1 gene delivered by biodegradable cationic heparin- polyethyleneimine nanogels. Oncol Rep 27: 363-370, 2012.
33. Lin XJ, Chen XC, Wang L, Wei YQ, Kan B, Wen YJ, He X and Zhao X: Dynamic progression of an intraperitoneal xenograft model of human ovarian cancer and its potential for preclinical trials. J Exp Clin Cancer Res 26: 467-474, 2007.
34. Hoffmann J, Schirner M, Menrad A and Schneider MR: A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res 57: 3847-3851, 1997.
35. He QM, Wei YQ, Tian L, Zhao X, Su JM, Yang L, Lu Y, Kan B, Lou YY, Huang MJ, Xiao F, Liu JY, Hu B, Luo F, Jiang Y, Wen YJ, Deng HX, Li J, Niu T and Yang JL: Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 278: 21831-21836, 2003.
36. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T and Jaffe RB: Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161: 1917-1924, 2002.
37. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
38. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
39. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P and Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: R15-R24, 2000.
40. Neri D and Bicknell R: Tumour vascular targeting. Nat Rev Cancer 5: 436-446, 2005.